EquityZen Growth Technology Fund LLC - Series 2386 has a substantially stronger public verification trail than many newly created private-market SPVs, but that should not be confused with proof that the investment itself is safe or attractively priced. The October 5, 2026 Form D reports a completed $406,368 offering involving 33 investors, identifies EquityZen Advisors LLC in the issuer's management structure and names EquityZen Securities LLC as the sales-compensation recipient. Separate regulatory records connect those entities to identifiable adviser and broker-dealer records, while Morgan Stanley independently confirmed that it completed its acquisition of EquityZen in January 2026. The principal unanswered questions are therefore not whether EquityZen exists or whether a Form D was filed. They concern the underlying company, actual securities acquired, entry valuation, share-class rights, liquidity, complete fee stack and eventual exit economics of Series 2386.
KEY FINDINGS
The SEC filing provides several unusually useful points of verification. Series 2386 is a Delaware limited liability company classified as a pooled investment fund and private equity fund. It relies on Rule 506(b) of Regulation D and Section 3(c)(1) of the Investment Company Act, reports September 24, 2026 as the date of first sale and states that the full $406,368 offering had already been sold when the filing was submitted on October 5. Thirty-three investors were reported, the minimum investment accepted from an outside investor was $10,032, and the filing reports $10,159 in sales commissions with no finder's fees.
Those numbers show that Series 2386 was not merely a newly created legal entity with no reported capital activity. The Form D describes an offering that had already reached its stated $406,368 amount. However, this is also where investors need to understand the limits of SEC visibility. Form D is a notice filing for an exempt securities offering. It is not an SEC registration statement, an approval of the investment, a regulator's valuation opinion or confirmation that investors are likely to make money. The presence of a CIK and SEC file number verifies a regulatory filing trail; it does not convert a private-market investment into an SEC-approved product.
REGULATORY STRUCTURE: ISSUER, ADVISER AND BROKER-DEALER ARE DIFFERENT ENTITIES
Series 2386, EquityZen Advisors and EquityZen Securities should be analyzed separately rather than grouped together under the EquityZen name. Series 2386 is the issuer of the investment interests. The Form D does not present it as an SEC-registered investment company. Instead, it reports reliance on Section 3(c)(1) of the Investment Company Act, an exclusion commonly used by privately offered investment funds.
EquityZen Advisors LLC appears in SEC investment-adviser records under CRD 289299 and SEC file number 802-111048. The regulatory distinction is important: the firm's Form ADV record identifies it as an Exempt Reporting Adviser. An ERA reports specified information to the SEC but is not the same as a fully SEC-registered investment adviser. Describing EquityZen Advisors simply as an "SEC-registered adviser" would therefore overstate its regulatory status.
EquityZen Securities LLC is a separate regulated entity. FINRA BrokerCheck identifies it as CRD 281820 and SEC number 8-69689. Series 2386's Form D names EquityZen Securities as the recipient of sales compensation and reports the same CRD number, creating a useful cross-check between the offering filing and FINRA's broker-dealer database. The current FINRA firm report reviewed for this article does not identify disclosure events attributed directly to EquityZen Securities LLC. That improves confidence in the regulatory identity of the intermediary, although it says nothing about whether the underlying investment will ultimately be profitable.
MORGAN STANLEY OWNERSHIP IS VERIFIED BUT DOES NOT GUARANTEE SERIES 2386
Morgan Stanley publicly confirmed that it completed its acquisition of EquityZen on January 27, 2026. This is a significant institutional verification point. EquityZen is therefore not an obscure platform whose ownership or operating company cannot be independently traced. It operates within a much larger financial group with extensive U.S. regulatory infrastructure.
The Morgan Stanley connection should nevertheless be interpreted narrowly. An investment in Series 2386 is not automatically a Morgan Stanley deposit, bond, publicly traded security or guaranteed investment product. Morgan Stanley's ownership of EquityZen does not guarantee the value of the private company underlying Series 2386, guarantee an IPO or acquisition, or guarantee that an investor can sell the investment when desired.
This distinction is particularly important in private markets. A well-known intermediary can arrange a transaction involving an asset that later falls sharply in value. A private company can raise additional capital at a lower valuation, dilute existing holders, remain private much longer than expected or fail entirely. Strong institutional ownership reduces questions about platform identity; it does not remove asset-level risk.
THE $10,159 COMMISSION CREATES A STRONG CROSS-CHECK
One of the most useful details in the filing is the reported sales commission. Series 2386 reports $406,368 sold and $10,159 in sales commissions. A direct calculation shows that $10,159 is approximately 2.5% of the reported amount sold.
That percentage is significant because Morgan Stanley announced in February 2026 that EquityZen was reducing transaction fees on its private-shares marketplace to 2.5% for applicable investors and shareholders. The Series 2386 figure therefore creates an unusually strong consistency check between information reported in an SEC filing and the platform's publicly announced fee structure.
This does not prove that every Series 2386 cost can be reconstructed from the public filing, nor does it establish that $10,159 represents every possible expense ultimately borne by investors. The offering documents remain controlling. Nevertheless, the near-exact numerical relationship is useful evidence that the Form D fits the publicly described EquityZen operating model rather than appearing as an isolated filing with unexplained compensation.
The investor count provides another useful data point. Dividing the $406,368 sold by 33 reported investors produces an average investment of approximately $12,314. That figure is reasonably close to the reported $10,032 minimum investment. Although individual commitments can differ substantially, the numbers are consistent with a pooled vehicle aggregating multiple relatively modest accredited-investor positions rather than relying on one institutional investor.
THE BIGGEST INFORMATION GAP: THE UNDERLYING ASSET
The most important unresolved issue is not regulatory identity. It is what Series 2386 actually owns. The public Form D identifies the vehicle as a private equity pooled investment fund but does not disclose the private company whose securities ultimately support the investment. It also does not provide the acquisition price per share, the implied valuation, percentage ownership, precise share class, liquidation preferences, conversion provisions or anti-dilution rights.
Those omissions matter because the economics of a private-company investment can depend heavily on the security acquired. A preferred financing round may establish a widely reported company valuation while providing investors in that round with liquidation preferences and other contractual protections. Secondary investors purchasing common shares or an indirect SPV interest may receive materially different economics even when the transaction is marketed using the same company valuation.
EquityZen describes a model in which investors can participate through pooled investment vehicles that acquire interests in private companies. In some transactions, an investment vehicle may also obtain exposure through another fund or SPV rather than owning the operating-company shares directly. A second structural layer can create additional manager dependency, contractual limitations and fees.
We did not identify publicly available Series 2386 offering documents in the sources reviewed that reveal the underlying company and complete security terms. This does not indicate that such documents do not exist. Private placement documents are frequently made available only to eligible prospective investors. It does mean that a public Form D review cannot determine whether Series 2386 purchased an attractive asset at an attractive valuation.
VALUATION RISK CAN MATTER MORE THAN THE PLATFORM NAME
Private-company valuation is inherently more difficult to verify than the price of a listed stock. There is usually no continuous public order book, transactions can occur infrequently, different share classes can have different economic rights and headline company valuations may be based on preferred financing terms unavailable to secondary purchasers.
An investor evaluating Series 2386 should therefore determine the actual security held by the vehicle and compare its effective acquisition price against relevant private-market evidence. Useful comparison points may include the latest preferred financing price, recent secondary trades, company tender offers and, where obtainable and meaningful, 409A valuations. A discount to a company's most recent headline valuation is not automatically attractive if the securities being purchased carry weaker rights than the securities used to establish that headline valuation.
EquityZen's own risk disclosures reinforce this concern. The platform warns that private investments can be difficult to value, may lack a readily available market and can result in the loss of the entire investment. These disclosures are more relevant to an investor's actual risk than the simple fact that a Form D appears in EDGAR.
LIQUIDITY SHOULD NOT BE ASSUMED
Series 2386 should also be treated as an illiquid private investment rather than the equivalent of publicly listed shares. Investors in listed securities generally have access to an exchange and observable market prices. Interests in an EquityZen investment vehicle may be subject to transfer restrictions, manager approval, company restrictions, rights of first refusal and the availability of qualified buyers.
The underlying company can also remain private for an unpredictable period. IPO plans can be postponed or abandoned, an acquisition may never occur and a private company can continue operating for many years without providing liquidity to secondary investors. Even a successful private company does not guarantee an investor will be able to exit at a desired time or price.
EquityZen has developed mechanisms through which some eligible fund interests may potentially be resold, but the existence of a secondary process should not be treated as guaranteed liquidity for Series 2386. Eligibility, buyer demand and pricing can change. Investors should be financially capable of holding the investment until an actual liquidity event occurs, potentially for a prolonged period.
THE FORM D COMMISSION MAY NOT REPRESENT THE COMPLETE FEE BURDEN
The $10,159 sales commission is visible because it was reported in the Form D. Investors should not automatically conclude that this represents the complete economic cost of the transaction. Depending on the Series 2386 structure, additional costs could potentially include organizational expenses, administrative costs, expenses associated with an underlying SPV or fund and other compensation disclosed only in the private offering documents.
This issue becomes more significant if Series 2386 does not own the underlying operating-company securities directly. A third-party vehicle between Series 2386 and the private company can introduce another economic layer, potentially including separate management or performance compensation.
Investors should therefore review the complete subscription agreement, operating agreement and offering materials and calculate the effective fee burden across every layer of the structure. A headline transaction fee may be easy to understand while the total economics are more complicated.
PEER COMPARISON: EQUITYZEN, FORGE, CLARITY AND NASDAQ PRIVATE MARKET
EquityZen operates within a broader private-secondary ecosystem that includes Forge, Clarity, formerly known as Hiive, and Nasdaq Private Market. These platforms are not directly interchangeable. Some emphasize marketplace price discovery, bids and asks or direct counterparty interaction, while others support company-sponsored tender offers, block trades or fund structures.
EquityZen's pooled-vehicle approach has potential advantages. Multiple investors can be aggregated into one entity, the underlying private company's capitalization table can remain simpler and accredited investors may gain exposure at commitment sizes below those typical of institutional block transactions. The trade-off is structural distance from the underlying security. An investor may own an interest in an EquityZen vehicle rather than being recorded directly as a shareholder of the private operating company.
That structure makes transparency around the underlying transaction especially important. Investors should understand not only the company name but also the actual security, transaction price, share rights, restrictions and number of intermediary layers. A familiar marketplace brand should not replace transaction-level analysis.
No private-market platform completely eliminates valuation or liquidity risk. Forge, Clarity, Nasdaq Private Market and EquityZen all operate in markets where information can be materially less complete than in public equities, securities may be restricted and transaction prices can differ between deals. The relevant comparison is therefore how much reliable information an investor can obtain about the specific transaction rather than which platform has the strongest brand recognition.
RELATED EQUITYZEN SERIES DO NOT MEAN THE FUNDS ARE IDENTICAL
SEC records contain numerous issuers using the EquityZen Growth Technology Fund naming structure. This repeated naming pattern is consistent with a platform establishing separate investment vehicles for different private-market transactions.
Investors should not assume that two EquityZen series are economically interchangeable. Different series can have different offering sizes, investor counts, minimum investments, underlying assets, fee arrangements and Investment Company Act exemptions. Some EquityZen vehicles have relied on Section 3(c)(1), while others have reported different exclusions.
Due diligence should therefore follow the exact issuer name, CIK and series number. Information discovered about one EquityZen vehicle should not automatically be attributed to Series 2386 merely because the vehicles share a manager or platform.
WHAT INVESTORS SHOULD VERIFY BEFORE INVESTING
The regulatory identity of Series 2386 can be checked relatively well from public records. The next stage of due diligence should focus on the transaction itself. Investors should obtain the Series 2386 offering and subscription documents and identify the underlying company, precise security class, number of shares or equivalent economic exposure, effective acquisition price, implied valuation and transfer restrictions.
It is also important to determine whether Series 2386 owns the underlying securities directly or through another fund or SPV. Any additional vehicle should be identified, and its manager, fees, carried interest or performance allocation, transfer restrictions and liquidation mechanics should be examined separately.
Investors should also understand the distribution process following a potential IPO, acquisition or other liquidity event, as well as manager discretion, conflicts of interest, tax treatment and what happens if the underlying company remains private for many years. These issues can materially affect realized returns but are not answered by Form D.
SCAM OR LEGIT ASSESSMENT
The public evidence reviewed strongly supports the conclusion that EquityZen Growth Technology Fund LLC - Series 2386 is connected to a real and identifiable private-market platform rather than being a fictitious issuer using fabricated regulatory credentials. Its Form D reports actual fundraising activity, EquityZen Securities can be independently cross-checked through FINRA, EquityZen Advisors appears in SEC adviser records, the sales commission closely aligns with EquityZen's publicly announced 2026 fee model and Morgan Stanley independently confirms its acquisition of EquityZen.
We did not identify evidence in the reviewed public sources establishing that Series 2386 itself is a fraudulent vehicle, that the reported Form D is fabricated or that the issuer is falsely claiming an EquityZen connection. That conclusion should be kept separate from an investment recommendation. Legitimate private-market structures can still lose substantial or even all investor capital.
The largest unresolved risks involve investment economics rather than identity: the underlying company, acquisition valuation, security class, liquidation rights, complete fee burden and timing of a possible exit remain unavailable from the public Form D alone.
WHAT WE THINK
Series 2386 scores strongly on regulatory traceability but cannot be fully evaluated on investment quality from publicly available information. This is a meaningful distinction. The evidence does not resemble the pattern normally associated with an anonymous issuer using unverifiable regulatory claims. The manager, broker-dealer and ultimate ownership chain can all be independently examined.
The investment risks instead come from the structure of private markets: uncertain valuation, potentially concentrated exposure to one private company, restricted liquidity, limited public financial disclosure, possible multiple SPV layers and dependence on a future liquidity event.
Morgan Stanley ownership and FINRA broker-dealer oversight are meaningful credibility signals, but they do not answer the most important investment question. Investors still need to determine exactly what Series 2386 purchased, at what effective valuation, with what contractual rights, through how many intermediary layers and at what total cost.
FINAL
EquityZen Growth Technology Fund LLC - Series 2386 has a stronger verification trail than many newly filed private-market SPVs. Its October 5, 2026 Form D reports $406,368 sold to 33 investors, a $10,032 minimum investment and $10,159 in sales commissions. EquityZen Securities LLC is independently identifiable through FINRA, EquityZen Advisors LLC reports to the SEC as an Exempt Reporting Adviser, and Morgan Stanley completed its acquisition of EquityZen in January 2026. The reported commission also aligns closely with EquityZen's publicly announced 2.5% transaction-fee structure.
Those facts support the authenticity of the regulatory and corporate trail, but they do not establish that Series 2386 is low-risk, fairly valued or likely to generate a successful exit. The public filing does not reveal the underlying company, exact security class, purchase valuation, liquidation rights, complete fee stack or guaranteed liquidity path. Investors should therefore treat the Form D as the starting point for due diligence rather than evidence of regulatory approval or investment safety.